Neuberger Berman Group’s Ocular Therapeutix OCUL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-51,400
| Closed | -$213K | – | 1847 |
|
|
2022
Q3 | $213K | Sell |
51,400
-150
| -0.3% | -$622 | ﹤0.01% | 1704 |
|
|
2022
Q2 | $207K | Sell |
51,550
-8,960
| -15% | -$36K | ﹤0.01% | 1738 |
|
|
2022
Q1 | $300K | Sell |
60,510
-33
| -0.1% | -$164 | ﹤0.01% | 1702 |
|
|
2021
Q4 | $422K | Buy |
60,543
+4
| +0% | +$28 | ﹤0.01% | 1597 |
|
|
2021
Q3 | $605K | Sell |
60,539
-650
| -1% | -$6.5K | ﹤0.01% | 1426 |
|
|
2021
Q2 | $868K | Sell |
61,189
-350
| -0.6% | -$4.97K | ﹤0.01% | 1357 |
|
|
2021
Q1 | $1.01M | Sell |
61,539
-2,051
| -3% | -$33.7K | ﹤0.01% | 1306 |
|
|
2020
Q4 | $1.32M | Buy |
63,590
+100
| +0.2% | +$2.07K | ﹤0.01% | 1186 |
|
|
2020
Q3 | $483K | Buy |
63,490
+30
| +0% | +$228 | ﹤0.01% | 1351 |
|
|
2020
Q2 | $529K | Buy |
63,460
+220
| +0.3% | +$1.83K | ﹤0.01% | 1266 |
|
|
2020
Q1 | $313K | Hold |
63,240
| – | – | ﹤0.01% | 1329 |
|
|
2019
Q4 | $250K | Sell |
63,240
-4,000
| -6% | -$15.8K | ﹤0.01% | 1416 |
|
|
2019
Q3 | $204K | Hold |
67,240
| – | – | ﹤0.01% | 1466 |
|
|
2019
Q2 | $296K | Buy |
67,240
+26,600
| +65% | +$117K | ﹤0.01% | 1394 |
|
|
2019
Q1 | $161K | Sell |
40,640
-900
| -2% | -$3.57K | ﹤0.01% | 1466 |
|
|
2018
Q4 | $165K | Hold |
41,540
| – | – | ﹤0.01% | 1506 |
|
|
2018
Q3 | $286K | Buy |
41,540
+2,375
| +6% | +$16.4K | ﹤0.01% | 1439 |
|
|
2018
Q2 | $264K | Hold |
39,165
| – | – | ﹤0.01% | 1565 |
|
|
2018
Q1 | $255K | Buy |
39,165
+5,300
| +16% | +$34.5K | ﹤0.01% | 1528 |
|
|
2017
Q4 | $151K | Sell |
33,865
-4,800
| -12% | -$21.4K | ﹤0.01% | 1706 |
|
|
2017
Q3 | $239K | Buy |
38,665
+8,765
| +29% | +$54.2K | ﹤0.01% | 1461 |
|
|
2017
Q2 | $277K | Buy |
+29,900
| New | +$277K | ﹤0.01% | 1424 |
|